Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (47,005)	$ (182,125)
Adjustments to reconcile net loss to net cash used by operating activities
Depreciation and amortization	8,563	4,171
Equity based compensation	5,306	5,913
Change in fair value of derivative liability	1,578	(5,317)
Accretion of lease liability	(107)	(958)
Write-off of investment	759	529
Write-off of receivable	518
Write-off of deposit	424
Impairment of inventory		483
Accrued interest income on notes receivable		(97)
Change in contingent consideration payable	774	214
Accretion of contingent consideration	758
Accretion of convertible debenture and interest	1,009	1,553
Accrued interest on notes payable	3,073
Interest accrued - lease receivable	(312)	(308)
Deferred taxes	6,530	(232)
Impairment of goodwill and intangibles	16,748	145,203
Tax adjustment to goodwill	(1,406)
Gain on sale of dispensaries	(13,454)
Gain on sales lease back	(3,345)
Equity issued to pay consulting fees	644
Changes in operating assets and liabilities	5,531	1,572
NET CASH PROVIDED BY (USED IN) CONTINUED OPERATING ACTIVITIES	(13,414)	(29,399)
Net cash provided by (used in) discontinued operating activities	(627)	2,005
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	(14,041)	(27,394)
CASH FLOWS FROM INVESTING ACTIVITIES
Long term deposits		(2,507)
Issuance of notes receivable, net of repayments	(3,503)	802
Advances to discontinued operations		(7,504)
Notes receivable repayments	782
Purchase of non-controlling interest		(400)
Sale of dispensaries and interests in cannabis licenses	25,423
Sale lease back transactions	32,189
Purchases of property and equipment	(13,875)	(20,906)
NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES	41,016	(21,572)
Net cash provided by (used in) discontinued investing activities	(1,679)	2,073
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	39,337	(19,499)
CASH FLOWS FROM FINANCING ACTIVITIES
Notes payable received (repaid), net of costs	(317)	46,113
Cannex loan		12,497
Sale of stock with warrants, net of issuance costs	12,134
Issuance of convertible notes	8,636
Proceeds from the exercise of warrants	1,352
Repayment of convertible debentures	(37,813)	(953)
Repayment of notes payable	(2,000)	(4,058)
NET CASH PROVIDED BY (USED IN) CONTINUED FINANCING ACTIVITIES	(18,008)	53,599
Net cash provided by discontinued financing activities	3,503
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(14,505)	53,599
NET INCREASE (DECREASE) IN CASH	10,791	6,706
CASH, BEGINNING OF YEAR	8,141	1,435
CASH, END OF YEAR	$ 18,932	8,141
Cannex Capital Holdings Inc
CASH FLOWS FROM INVESTING ACTIVITIES
Business combination, net cash acquired		9,119
Om of Medicine LLC
CASH FLOWS FROM INVESTING ACTIVITIES
Business combination, net cash acquired		$ (176)